Clinical trial · Interventional

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma

NCT00193193CI-TRIAL-00003741completedPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone refractory prostate cancer.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Prostate Cancer	Malignant Prostate Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
Carboplatin	Drug	Carboplatin	ALIAS
Estramustine	Drug	Estramustine	ALIAS
Paclitaxel	Drug	Paclitaxel	ALIAS

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Overall response rate

Secondary outcomes (2)

measure
Toxicity
measure
Overall survival

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Adenocarcinoma of the prostate not curable with local treatment
* Disease progression while receiving hormonal therapy
* Measurable or evaluable disease
* Previous treatment with a maximum of one prior chemotherapy regimen
* ECOG performance status 0, 1, or 2.
* Adequate bone marrow, liver and kidney function
* Able to comprehend the nature of this study and give written informed consent

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* Age \< 18 years
* History of treatment for an invasive malignancy within five years
* Significant heart disease

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

References

Publications (0)

Data not yet available

No reference posted for this study.